` TRL (DaVita Inc) vs DAX Index Comparison - Alpha Spread

TRL
vs
D
DAX Index

Over the past 12 months, TRL has underperformed DAX Index, delivering a return of -30% compared to the DAX Index's +12% growth.

Stocks Performance
TRL vs DAX Index

Loading
TRL
DAX Index
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
TRL vs DAX Index

Loading
TRL
DAX Index
Difference
www.alphaspread.com

Performance By Year
TRL vs DAX Index

Loading
TRL
DAX Index
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
DaVita Inc vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

DaVita Inc
Glance View

In the intricate network of healthcare services, DaVita Inc. stands as a pivotal player, focusing on the often-overlooked but critical field of kidney care. Rooted in its mission to improve patients' quality of life by innovating kidney care therapies, DaVita has cultivated a robust operation primarily revolving around dialysis services. Chronic Kidney Disease (CKD) and kidney failure are rising global health concerns, necessitating regular dialysis treatments for affected individuals. DaVita serves this need through a network of dialysis centers, offering both in-center and at-home dialysis options. By prioritizing patient comfort and convenience alongside medical efficiency, DaVita has positioned itself as a go-to choice for those requiring ongoing renal care, effectively making the process as seamless as possible for patients. The business model of DaVita hinges on its ability to deliver consistent, high-quality care while managing costs—a balance crucial to success in the healthcare industry. Revenue flows in from both governmental programs such as Medicare and private health insurers, which fund the dialysis treatments for insured patients. DaVita's strategic strength lies in its operational scale, with a vast number of outpatient dialysis centers across the U.S. and internationally. This extensive reach not only strengthens its market position but also provides a wealth of data and feedback, fueling further innovation and efficiency improvements. By leveraging this extensive network, DaVita continues to tap into the growing demand for accessible, comprehensive kidney care services, reinforcing its commitment to patient-centered healthcare delivery while sustaining its financial growth.

TRL Intrinsic Value
232.95 EUR
Undervaluation 49%
Intrinsic Value
Price
Back to Top